Marie‐Ange Mouret‐Reynier

Author

Also Known As

Isabelle Desmoulins, J.-F. Moulin, M. -A. Mouret-Reynier, M. A. Mouret-Reynier, M. Mouret-Reynier, M.-A. Mouret-Reynier, M.A. Mouret-Reynier, M.A. Mouret-reynier, MARIE-ANGE MOURET-REYNIER, Marie Ange Mouret-Reynier

194

Publications

7.5K

Citations

H-Index

Concepts

All Affiliations

Centre Jean Perrin Inserm Institut Curie Centre Léon Bérard Institut Claudius Regaud

About

Marie‐Ange Mouret‐Reynier is an author at Centre Jean Perrin specializing in oncology, medicine, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	38	3.8K
2	Health Sciences	13	14	1.2K
3	Public Health	2	2	328
4	Biostatistics	2	2	328
5	Endocrinology	1	1	17

Marie‐Ange Mouret‐Reynier

Publications

6.5K

Citations

H-Index

Page 1

	Year	Citations
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial François‐Clément Bidard, Virginia Kaklamani, Patrick Neven, Journal of Clinical Oncology	2022	626
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, The Lancet Oncology 5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials	2017	578
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis Céline Lefèbvre, Thomas Bachelot, Thomas Filleron, PLoS Medicine	2016	388
Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer Mathilde Bayet‐Robert, Fabrice Kwiatowski, Marianne Leheurteur, Cancer Biology & Therapy	2010	386
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial Angelo Di Leo, Stephen Johnston, Keun Seok Lee, The Lancet Oncology Advanced Breast CancerBreast OncologyOncologyMedicineGynecology	2017	377
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer Peter Schmid, Javier Cortes, Rebecca Dent, New England Journal of Medicine	2024	310
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial François‐Clément Bidard, Anne‐Claire Hardy‐Bessard, Florence Dalenc, The Lancet Oncology Breast OncologyEsr1 MutationEndocrine-related CancerMedicinePharmacology	2022	285
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort Élisa Gobbini, Monia Ezzalfani, Véronique Dièras, European Journal of Cancer Prognostic EvaluationBreast OncologyMedicineTime TrendsEpidemiology Of Cancer	2018	274
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer Paul Cottu, Véronique D’Hondt, Sylvain Dureau, Annals of Oncology	2018	160
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial Jacobus Pfisterer, Catherine Shannon, Klaus Baumann, The Lancet Oncology MedicineMetronomic TherapyGynecologyRecurrent Ovarian CancerCancer Treatment	2020	157

Page 1